Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, has been approved to trade on the OTCQX® Best Marketplace in the United States under the symbol “IMMVF”. The Company will continue to trade on the Toronto Stock Exchange under the symbol “IMV”.
The OTCQX is an established marketplace for global and growth companies with high financial standards. Investors can find current financial disclosure and Real-Time Level 2 quotes for Immunovaccine at www.otcmarkets.com.
“The OTCQX offers U.S. investors easier access to Immunovaccine as we expand our presence in the rapidly evolving field of cancer immunotherapy”, said Marc Mansour, CEO of Immunovaccine. “Trading on the OTCQX enables us to introduce the company to a broader range of investors and retail brokers in the US, at a time when our sector has emerged as one of the most promising in cancer therapy.”
Dorsey & Whitney LLP serves as Immunovaccine’s Principal American Liaison (“PAL”) on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.
In addition, Immunovaccine announced that its Company information will be made available via S&P Capital IQ's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of S&P Capital IQ's MarketScope Advisor. MarketScope Advisor is an Internet-based research engine used by more than 100,000 investment advisors. As part of the program, a full description of Immunovaccine will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in up to 41 states under their Blue Sky Laws.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
About DepoVax™
DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax™ platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.
About S&P Capital IQ
S&P Capital IQ, a brand of the McGraw-Hill Companies (NYSE:MHP), is a leading provider of multi-asset class data, research and analytics to institutional investors, investment advisors and wealth managers around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Securities Evaluations, Global Data Solutions, and Compustat; and research offerings including Leveraged Commentary & Data, Global Market Intelligence, and company and fund research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. Company information distributed through the Market Access Program is based upon information that S&P Capital IQ considers to be reliable, but neither S&P Capital IQ nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.
No comments:
Post a Comment